

# Gagik R Galstyan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/756704/publications.pdf>

Version: 2024-02-01

74  
papers

939  
citations

687363

13  
h-index

454955

30  
g-index

83  
all docs

83  
docs citations

83  
times ranked

778  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	1.9	195
2	The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus, 2016, 19, 104-112.	1.9	155
3	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes Mellitus, 2017, 20, 1-121.	1.9	142
4	Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice, 2016, 115, 90-95.	2.8	67
5	Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. Journal of Diabetes and Its Complications, 1994, 8, 45-50.	2.3	34
6	Type 2 diabetes and prediabetes prevalence in patients with different risk factor combinations in the NATION study. Diabetes Mellitus, 2020, 23, 4-11.	1.9	23
7	Trends in the epidemiology of diabetic foot and lower limb amputations in Russian Federation according to the Federal Diabetes Register (2013â€“2016). Diabetes Mellitus, 2018, 21, 170-177.	1.9	22
8	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	1.9	20
9	COVID-19: urgent questions for estimating morbidity, prevalence, case fatality rate and mortality rate. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2585.	1.4	20
10	Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: A narrative review (éç„æ·èf°â²»ç´ç±»ä¼¼ç%©âœ²âž«ç³—â°¿ç—...æ²»ç—ä,çš„ä¼œç””î¼šâ™è¿°æ€šç»¼è¿°). Journal of Diabetes, 2020, 23, 4-102.	1.8	17
11	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	1.9	16
12	Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes Mellitus, 2022, 25, 27-49.	1.9	13
13	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology, 2019, , 83-91.	1.4	12
14	Obesity and type 2 diabetes: can we find a compromised treatment solution?. Diabetes Mellitus, 2017, 20, 270-278.	1.9	12
15	Costs of Hospital Stay in Specialized Diabetic Foot Department in Russia. Value in Health Regional Issues, 2015, 7, 80-86.	1.2	10
16	Regional differences in cardiac mortality rates in Russia: the role of statistical features. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2928.	1.4	9
17	Â«DIARISKÂ» â€” the first national prediabetes and diabetes mellitus type 2 risk calculator. Diabetes Mellitus, 2021, 23, 404-411.	1.9	8
18	Diabetes mellitus type 1 in adults. Diabetes Mellitus, 2020, 23, 42-114.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Self-Treated Hypoglycemia in Type 2 Diabetes Mellitus: Results from the Second Wave of an International Cross-Sectional Survey. <i>Diabetes Therapy</i> , 2016, 7, 279-293.	2.5	6
20	The blood perfusion and NADH/FAD content combined analysis in patients with diabetes foot. <i>Proceedings of SPIE</i> , 2016, , .	0.8	6
21	Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus. <i>Diabetes Mellitus</i> , 2019, 22, 305-327.	1.9	6
22	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1491-1497.	0.8	6
23	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2016, 7, 583-590.	2.5	5
24	Cardiovascular mortality rate in Moscow and St. Petersburg in 2015 and 2018. <i>Russian Journal of Cardiology</i> , 2021, 26, 4048.	1.4	5
25	Resolution on the results of the first working meeting of the scientific advisory board Â«Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapyÂ». <i>Diabetes Mellitus</i> , 2019, 22, 281-288.	1.9	5
26	Priority areas for the prevention of non-communicable diseases on the agenda of the 75th World Health Assembly: plans for the future. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 7.	0.6	5
27	Changes in mortality rates from acute types of coronary artery disease in Russia for the period from 2015 to 2019. <i>Russian Journal of Cardiology</i> , 2021, 26, 4441.	1.4	4
28	Multidisciplinary lifestyle management approach in patients with type 2 diabetes mellitus in real clinical practice. Results of application â€œLife is easyâ€•programme in Russia. <i>Diabetes Mellitus</i> , 2019, 22, 115-126.	1.9	4
29	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis. <i>Diabetes Mellitus</i> , 2019, 22, 504-514.	1.9	4
30	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. <i>Diabetes Mellitus</i> , 2017, 20, 286-298.	1.9	4
31	The Scientific Advisory board resolution: Implementation of intermittently scanned Continuous Glucose monitoring in clinical practice to improve glycemic control. <i>Diabetes Mellitus</i> , 2021, 24, 185-192.	1.9	3
32	Methods and problems of the nosological analysis of mortality in the period of COVID-19 pandemic. <i>Nacional'noe Zdravoohranenie</i> , 2021, 2, 51-58.	1.2	3
33	The initial level of heart rate variability determines the dynamics of the neuropathy of the autonomic nervous system and temperature sensitivity in rats with streptozotocin diabetes. <i>Diabetes Mellitus</i> , 2019, 22, 233-243.	1.9	3
34	Diabetic osteoarthropathy: modern methods of therapy. <i>Diabetes Mellitus</i> , 2010, 13, 70-73.	1.9	3
35	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. <i>Russian Journal of Cardiology</i> , 2020, 25, 3919.	1.4	3
36	Indications for various options of foot deformities orthopedic correction in diabetic neuroosteoarthropathy. <i>Diabetes Mellitus</i> , 2020, 23, 374-385.	1.9	3

#	ARTICLE	IF	CITATIONS
37	Consensus position of endocrinologists and pathologists on coding causes of death in patients with diabetes mellitus (expert opinion). <i>Diabetes Mellitus</i> , 2021, 24, 300-309.	1.9	2
38	Organizational aspects of vaccination against a new coronavirus infection. <i>Nacionalnoe Zdravoohranenie</i> , 2021, 2, 5-11.	1.2	2
39	Oral semaglutide: the innovation in type 2 diabetes management. <i>Diabetes Mellitus</i> , 2021, 24, 273-281.	1.9	2
40	Keratinocytes differentiation and wound healing in rats with streptozotocin induced diabetes and severe hyperglycemia. <i>Diabetes Mellitus</i> , 2020, 23, 19-28.	1.9	2
41	Expert council resolution on regional program of early T2D detection, prevention and treatment in Russian Federation. <i>Diabetes Mellitus</i> , 2017, 20, 233-237.	1.9	2
42	Near-infrared fluorescence imaging with indocyanine green in diabetic patient with critical limb ischemia: a case report. <i>Diabetes Mellitus</i> , 2018, 21, 319-324.	1.9	2
43	Hypoglycemia and the risk of cognitive impairment and dementia in elderly and senile patients with type 2 diabetes. <i>Diabetes Mellitus</i> , 2020, 23, 72-87.	1.9	2
44	Atherosclerosis pathogenesis from the perspective of microvascular dysfunction. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 3076.	1.4	2
45	Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. <i>Diabetes Mellitus</i> , 2022, 24, 479-486.	1.9	2
46	Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation. <i>Diabetes Mellitus</i> , 2022, 25, 61-71.	1.9	2
47	Dynamics of regional mortality rates for men and women from diseases and external causes in Russia for the period 2016-2019 compared to 2020. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 29.	0.6	2
48	Clinical and demographic analysis of telemedicine «doctor-patient» consultations at the Endocrinology Research Centre. <i>Problemy Endokrinologii</i> , 2022, 68, 4-15.	0.8	2
49	Different treatment strategies in primary hyperparathyroidism during pregnancy. <i>Endocrine</i> , 2022, 77, 556-560.	2.3	2
50	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment. <i>Diabetes Mellitus</i> , 2021, 24, 193-197.	1.9	1
51	Insulin glargine 300 U/ml in type 2 diabetes mellitus patients: results of the EDITION program (review). <i>Problemy Endokrinologii</i> , 2017, 63, 257-268.	0.8	1
52	Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy. <i>Problemy Endokrinologii</i> , 2017, 63, 307-319.	0.8	1
53	Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. <i>Diabetes Mellitus</i> , 2016, 19, 229-236.	1.9	1
54	Wound healing mechanisms in rats with streptozotocin-induced diabetes mellitus. <i>Problemy Endokrinologii</i> , 2018, 64, 292-298.	0.8	1



#	ARTICLE	IF	CITATIONS
73	Clinical case of long-term unrecognized primary hyperparathyroidism. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 74.	0.6	0
74	Role of genetic factors (biology of telomeres) in cardiac rehabilitation. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 21, 3272.	1.4	0